Breast and endometrial cancers share common risk factors and therefore
a slight excess risk of endometrial cancer is expected among breast c
ancer patients. Yet, this does not explain the risk of endometrial can
cer linked to tamoxifen use. When background risk is adequately contro
lled, an effect of tamoxifen is still seen, increasing with duration o
f use and further supported by experimental evidence of carcinogenicit
y. (C) 1998 Elsevier Science Ltd. All rights reserved.